Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022)
Relmada Therapeutics (RLMD) posted quarterly Income from Non-Controlling Interests of -$39.7 million for Q1 2022, down 78.91% year-over-year from -$188.5 million in Q1 2021, and down 78.91% quarter-over-quarter from -$22.2 million in Q1 2021.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Income from Non-Controlling Interests for 2 consecutive years, with -$39.7 million the latest figure, recorded in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |